Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors

PRIMARY OBJECTIVES: I. Determine the objective response rate (complete response plus partial response) of dasatinib in adenoid cystic carcinoma (ACC). II. Determine the progression-free survival of dasatinib in ACC. SECONDARY OBJECTIVES: I. Determine the duration of response. II. Determine the stable disease rate and duration of stable disease. III. Determine progression-free survival. IV. Determine the median survival. V. Determine the overall survival. VI. Determine the safety and tolerability. TERTIARY OBJECTIVES: I. To examine biomarkers that relate to SRC proto-oncogene, non-receptor tyrosine kinase (Src) signal transduction and to correlate these biomarkers with clinical response to dasatinib in ACC and non-ACC malignant salivary gland tumors (MSGT). II. Determine if activating mutations in platelet-derived growth factor alpha polypeptide (PDGFA) and KIT are associated with response in ACC. OUTLINE: Patients receive dasatinib orally (PO) twice daily (BID) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed at 8 weeks.